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Abstract 48 
We aimed to identify whether genetic polymorphisms within L-SIGN or DC-SIGN correlate with 49 
HCV susceptibility. An MSM and an IDU cohort of HCV cases and multiple-exposed uninfected 50 
controls were genotyped for numerous L-SIGN and DC-SIGN polymorphisms. DC-SIGN SNPs -51 
139, -871 and -939 correlate with HCV acquisition in the MSM cohort only. When the same 52 
SNPs were introduced into a transcription activity assay they demonstrated a reduction in 53 
expression with predicted alteration in binding of transcription factors. DC-SIGN promoter 54 
SNPs correlate with risk of HCV acquisition via sexual but not IDU exposure, likely through 55 
modulation of mRNA expression levels.  56 
 57 
Keywords: HCV; HIV-1; Lectins, DC-SIGN; polymorphism, single nucleotide; MSM; sexual 58 
transmission 59 
60 
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Introduction 61 
Hepatitis C virus (HCV) represents a major global health burden, with 350.000 people dying 62 
annually from HCV-related liver disease.[1] Intravenous drug use is now the major 63 
transmission route. Nevertheless, since 2000, sexual transmission has been reported 64 
frequently among HIV-infected men who have sex with men (MSM) and is associated with 65 
high-risk sexual behavior. Interestingly, some individuals remain uninfected despite practicing 66 
high-risk behavior(s). Studies have shown that ultimately 10-20% of injecting drug users (IDU) 67 
do not seroconvert, suggesting a biological reason why some individuals are less prone to 68 
contract HCV. [2] 69 
DC-SIGN (dendritic cell specific ICAM-grabbing non-integrin, CD209) and L-SIGN (DC-70 
SIGN related, CD209L) are c-type lectins, which have been implicated to play a role in HCV 71 
transmission and infection.[3] DC-SIGN is a calcium-dependent cell surface lectin on the 72 
surface of dendritic cells (DCs).[4] DCs are localized in skin and mucosal tissues and may serve 73 
as a replication reservoir for HCV.[4,5] L-SIGN is mainly expressed on liver and lymph node 74 
sinusoidal endothelial cells. It shares 77% amino acid identity with DC-SIGN and it has been 75 
shown to capture several viruses including HCV.[3] Whereas the DC-SIGN neck region on exon 76 
4 is highly conserved (7 repeats in the majority of individuals) the L-SIGN neck region is very 77 
variable.[6] This repeat region has been suggested to affect disease susceptibility and outcome 78 
for HIV-1 infection. [7–10] 79 
The objective of this study was to analyze the frequency of previously reported genetic 80 
variations in DC/L-SIGN genes in individuals from two well-defined cohorts at risk of HCV 81 
infection who either seroconverted or remained uninfected. We identified three DC-SIGN SNPs 82 
that were associated with HCV susceptibility through high risk sexual exposure but not with 83 
IDU. Furthermore, we assessed whether these SNPs in the DC-SIGN promoter affect its activity. 84 
 85 
Patients and Methods 86 
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Study populations 87 
1. MSM cohort (MOSAIC) 88 
Sixty-two HIV-1 infected, Western European MSM participating in the MSM Observational 89 
Study of Acute Infection with Hepatitis C (MOSAIC) cohort were included. Risk behavior data 90 
was available from behavioral questionnaires collected at 6 month intervals. Participants were 91 
categorized as multiple exposed uninfected (MEU, n = 30) or multiple exposed infected (MEI, 92 
n=32) based on reported behavioral risk factors at inclusion or any of the follow up visits, 93 
which have been shown to be associated with increased risk of acquiring HCV sexually in the 94 
MOSAIC cohort. Distribution of risk factors (i.e. no or inconsistent condom use, anal 95 
intercourse with an HCV-infected sex partner, fisting, use of sex toys, rectal bleeding during or 96 
after sex, and group sex) is summarized in supplemental Table 1. The MOSAIC study was 97 
approved by the Institutional Review Board of the Academic Medical Center under assigned 98 
study numbers NL26485.018.09 and NL48572.018.14. 99 
 100 
2. IDU cohort (ACS) 101 
Sixty-two Western European participants from the Amsterdam Cohort Studies (ACS) among 102 
IDU were selected, who started injecting drugs intravenously before 1990, which was a period 103 
with high incidence of HCV among drug users (up to 27.5/100 person years in the 1980s in this 104 
cohort).[11] The ACS among IDU was an open prospective cohort study recruiting drug users 105 
between 1985 and 2016 investigating the epidemiology, the natural history and pathogenesis 106 
of HIV-1 infection and other blood-borne and/or sexually transmitted diseases. Participants 107 
who injected more than 2 years and remained HCV seronegative during follow-up (n = 40) 108 
were classified as MEU where as 22 MEI seroconverted for HCV during follow up. Total 109 
duration of injecting drugs and follow up was similar for MEU and MEI (supplemental Table 1). 110 
The ACS study was approved by the Institutional Review Board of the Academic Medical 111 
Center under assigned study numbers MEC 07/182 and MEC 09/040. 112 
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 113 
DNA isolation and genotyping 114 
DNA was isolated from 200 µl participant serum utilising the QIAamp DNA blood mini kit 115 
according to the manufacturer’s protocol (Qiagen). The number of repeat domains within the 116 
L-SIGN repeat region was determined for each subject by PCR. PCR reactions contained 5 µl of 117 
template DNA, 400nM forward primer, 400nM reverse primer, 2.5 mM MgCl2, 0.2 mM dNTPs, 118 
0.1 mg/mL Bovine Serum Albumin (BSA), 1.25 units FastStart Taq DNA polymerase in a total 119 
volume of 25 µL 1x Faststart PCR buffer. 120 
L-SIGN SNP rs2277998 was assessed using the Ready-to-use hot start reaction mix for 121 
High Resolution Melting (HRM) curve analysis using the LightCycler® 480 (Roche). The reaction 122 
contained 2.0 µl DNA template, 2.5 mM MgCl2, 8 ng α-casein, 450 nM Fwd primer (Biolegio) 123 
and 450 nM Rev primer (Biolegio) in a total volume of 20 µL 1x HRM master mix. 124 
To assess reported DC-SIGN SNPs in the promoter region at positions -939 (rs735240), 125 
-871 (rs735239), -336 (rs4804803) and -139 (rs2287886), a DNA fragment covering 126 
approximately 1000 bp upstream of the ATG translation start site was amplified with two 127 
primer sets. The amplicons were sequenced in both directions with the same primers using Big 128 
dye terminator according to manufacturer’s instructions (Applied Biosystems, Inc., Norwalk 129 
CT).  Primers and amplification conditions are summarized in supplemental Table 2. 130 
 131 
Cell culture 132 
HEK 293T/17 cells (ATCC number: CRL-11268) were cultured in DMEM (Invitrogen) 133 
supplemented with 10% FCS, 1x MEM Non-Essential Amino Acids (Gibco), 100 U/ml penicillin 134 
and 100 U/ml streptomycin. Cells were incubated at 37°C in 5% CO2 and passaged twice a 135 
week upon 90% confluence. 136 
 137 
Construction DC-SIGN promoter expression construct 138 
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The DC-SIGN promoter variants were constructed by amplifying the DC-SIGN promoter region 139 
from DNA from one study participant with the -139A, -871A and -939G variants using primers 140 
tailed with XhoI and HindIII restriction sites. The amplicons were cloned into the pGL10.4 141 
vector[luc2] (Promega) at the XhoI and HindIII sites. Promoter variants (see supplemental 142 
Figure 1) were established by site directed mutagenesis. Mutations were made with the 143 
QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies) with specific mutagenic 144 
primers (see Supplemental Table 2). 145 
 146 
Transfection of 293T cells with promoter constructs and analysis of luciferase expression 147 
293T/17 cells were transfected with the various DC-SIGN promoter constructs and a Renilla 148 
luciferase expression plasmid (pRL-CMV) (Promega) for normalization in a 50:1 ratio using 149 
Xtremegene (Invitrogen) according to manufacturer’s protocol. Cells were incubated 24 hours 150 
and lysed with Passive lysis buffer (Promega). 5 µl of the lysate was used to measure Firefly 151 
and Renilla luciferase activity with Dual-Glo luciferase assay system (Promega) according to 152 
manufacturer’s protocol. 153 
 154 
Prediction of transcription factor (TF) binding sites 155 
TF binding sites were predicted using the PROMO database (http://alggen.lsi.upc.es/) which 156 
uses TRANSFAC for prediction. [16] 157 
 158 
Statistical analysis 159 
DC/L-SIGN SNP genotype frequencies between MEU and MEI were compared using logistic 160 
regression. Initially, an additive/dominance deviation joint 2 degree of freedom test (with two 161 
genotype-dependent variables in the regression, one with 0/1/2 coding and the second with 162 
0/1/0 coding) was carried out. Subsequently, in case of dominance deviation (p<0.1), a 163 
dominant or recessive genetic model was assumed, otherwise an additive genetic model was 164 
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assumed in the logistic regression model used to estimate the odds ratio (OR) and 165 
corresponding 95% confidence interval. A p value <0.05 was considered statistically significant 166 
and all analyses were carried out using SPSS software (IBM, version 20). 167 
 168 
Results 169 
DC-SIGN -139GG, -871GG and -939AA are associated with reduced HCV susceptibility in MSM 170 
Patient characteristics are summarized in supplemental Table 1. In the MSM cohort, three DC-171 
SIGN SNPs were significantly associated with HCV infection (Table 1). The -139GG was found 172 
more frequently in MEU (63.3% in MEU compared to 37.5% in MEI). Additionally, -871GG 173 
(36.7% in MEU compared to 12.5% in MEI) and the -939AA (53.3% in MEU compared to 21.9% 174 
in MEI) were found more often in MEU, indicating that -139GG, -871GG and -939AA genotypes 175 
protect against HCV acquisition (OR: 0.35 p= 0.045, OR: 0.23 p=0.027 and OR: 0.23 p=0.009 176 
respectively). The -336 SNP was not significantly associated with HCV susceptibility. In the ACS 177 
IDU cohort, no significant associations were found between SNPs and HCV susceptibility. 178 
 179 
No associations between L-SIGN polymorphisms and HCV susceptibility 180 
No association with HCV susceptibility was found for L-SIGN SNP rs2277998. In addition, the L-181 
SIGN repeat distribution between MEI and MEU was similar for both cohorts (supplementary 182 
Table 3). No significant difference in zygosity for the L-SIGN repeat was found between MEI 183 
and MEU (OR: 0.982 p=0.961) (supplementary Table 4). 184 
 185 
DC-SIGN promoter SNPs affect promoter activity 186 
We tested the effect of the promoter variants within the DC-SIGN promoter on transcription 187 
activity by using luciferase promoter constructs (Figure 1). The -139G caused a 2.6 fold 188 
reduction (p<0.001), the -871G a 3.3 fold reduction (p<0.001) and the -939A a 1.4 fold 189 
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reduction (p=0.086). This data suggests that the DC-SIGN promoter variants affect 190 
transcription levels and thereby protein and cell surface expression patterns. 191 
Next, we investigated whether the observed decrease in DC-SIGN promoter activity for specific 192 
SNPs could be due to alterations in TF binding sites, by a in silico comparison of predicted TF 193 
binding sites of promoter variants (Figure 1B). The variants at the -139, -871 and -939 sites do 194 
affect multiple predicted TF binding sites, with some putative sites lost (GR, C/EBP, Pr-B, Pr-A, 195 
HOXD9, HOXD10) and some TF binding sites gained (GR-Alpha, AP-2Alpha). This would indicate 196 
that the SNPs identified within the DC-SIGN promoter region can modulate activity through 197 
differential binding of transcription factors. 198 
 199 
Discussion 200 
Here we investigated whether polymorphisms in DC-SIGN and L-SIGN correlated susceptibility 201 
to HCV infection in two well-defined cohorts consisting of individuals at high risk of HCV 202 
infection through sexual or intravenous exposure. We selected polymorphisms based on what 203 
has been reported within the literature for HCV as well as other infectious agents. In the MSM 204 
cohort we identified an association of HCV susceptibility with three DC-SIGN SNPs. These SNPs 205 
were not associated with HCV susceptibility in the IDU cohort. No effects were found for the 206 
DC-SIGN -336 SNP, the L-SIGN SNP rs2277998 and repeat polymorphism in either cohort. 207 
We studied four SNPs in the DC-SIGN promoter region, of which three (-139, -871 and -208 
939) were found to correlate with HCV susceptibility in MSM, with -139G showing the 209 
strongest effect. Although the same SNPs have previously been associated with other 210 
infectious diseases, this is the first time SNPs have been reported to be associated with 211 
susceptibility to sexual transmission of HCV. Interestingly, the -139G SNP has also been 212 
reported to protect against sexual transmission of HIV-1.[14] 213 
It has been published previously that the combination of  -139G and -939A in the DC-214 
SIGN promoter region significantly reduces DC-SIGN expression on immature DCs compared to 215 
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-139A and -939G.[15] We now show that the -139G and -871G SNP independently cause a 216 
reduction in promoter activity, while the -939A variant failed to reach statistical significance (p 217 
= 0.085). The DC-SIGN promoter encodes multiple TF binding sites which are in silico predicted 218 
to be affected by the -139, -871 and -939 variants. This strongly suggests that the decreased 219 
promoter activity observed in vitro is (at least partly) caused by a reduction in TF binding, 220 
which will require further testing. 221 
As our study was small, our observations clearly need to be confirmed in larger 222 
cohorts. However, the functional data supports the associations of the SNPs with protection 223 
against HCV acquisition. Collectively, our data suggest that DC-SIGN plays a role in HCV 224 
acquisition via sexual and not intravenous exposure. This effect appears to be mediated by 225 
reduced DC-SIGN expression, which suggest that DC-SIGN on DCs plays a role in sexual 226 
transmission of HCV, similar to its role in HIV infection. [4]. We hypothesize that DCs transfer 227 
HCV to the liver through DC-SIGN; individuals with the protective genotypes will have lower 228 
DC-SIGN expression, resulting in a reduced susceptibility to sexual acquisition of HCV. 229 
Alternatively, DC-SIGN expression on DCs at mucosal surfaces may influence HCV antigen 230 
capture and induction of localized immune responses and modulate mucosal protection 231 
against HCV acquisition, which does not play a role in intravenous exposure. Further studies 232 
into the exact mechanism behind DC-SIGN affecting HCV infection susceptibility are warranted 233 
to better understand how DC-SIGN expression levels might influence immune responses, as 234 
well as mechanisms of transmission. 235 
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Table and Figure Legends 293 
Table 1  Distribution of DC/L-SIGN SNPs in MEI and MEI individuals 294 
rs2287886 GG, rs735240 AA and rs735239 GG genotypes are significantly associated with protection against HCV 295 
acquisition in the MOSAIC (MSM) cohort. No significant associations within the ACS (IDU) cohort. 296 
 297 
Figure 1 Effect SNPs on DC-SIGN promoter activity A, The -139 SNP causes a reduction of 2.6 fold (p=0.0005), the -871 298 
SNP of 3.3 fold (p=0.0009) and the -939 SNP a 1.4 fold (not significant). B, Protective SNPs affect TF binding sites in the 299 
DC-SIGN promoter. Putative binding of TFs to DC-SIGN promoter sequences with and without SNPs. Some TFs do not 300 
bind anymore to the sequence containing protective SNPs (orange), some bind both sequences (blue) and some bind 301 
exclusively to the SNP containing the protective variant (green). 302 
 303 
Supplemental Table legends 304 
Supplemental Table 1 Patients characteristics from the MOSAIC and ACS cohorts 305 
Supplemental Table 2 Primers and PCR conditions used for analysis of the DC/L-SIGN polymorphisms 306 
Supplemental Table 3 Distribution L-SIGN repeat region among MEI and MEU individuals 307 
Supplemental Table 4 Zygosity L-SIGN repeat region compared between MEI and MEU individuals 308 
No difference in L-SIGN zygosity between MEI and MEU individuals. 309 
 310 
Supplemental Figure legends 311 
Supplemental Figure 1 Graphical representation of the DC-SIGN promoter and expression plasmid pGL4.10 construct 312 
 313 
 314 
 315 
 316 
 317 
 318 
 319 
 320 
 321 
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Table 1 322 
MOSAIC             MEI vs MEU     
  
genotype MEI (n) MEI (%) MEU (n) MEU (%) 
Dominance 
deviation 
a
 
OR 95% CI  p value  
L-SIGN 
rs2277998 
AA 1 3% 4 13% 
 
 0.29 to 2.37 0.73 AG 11 34% 6 20% 0.09
b
 0.83  
GG 20 63% 20 67%   (GG vs AG+AA) 
DC-SIGN -
139 
AA 3 9% 6 20% 
 
 0.12 to 0.97   0.04
c
  AG 17 53% 5 17% 0.01
b
 0.35  
GG 12 38% 19 63%  (GG vs AG+AA) 
DC-SIGN -
336 
AA 22 69% 25 83% 
 
 0.74 to 7.32 
 
AG 9 28% 5 17% 0.99 2.32  
GG 1 3% 0 0%  (per G allele) 
DC-SIGN -
871 
AA 16 50% 12 40% 
 
 0.06 to 0.85 0.03
 c
 AG 12 38% 6 20% 0.08
b
 0.23  
GG 4 13% 11 37%  (GG vs AG+AA) 
DC-SIGN -
939 
AA 7 22% 16 53% 
 
 0.07 to 0.69  0.01
 c
 AG 18 56% 5 17% <0.01
b
 0.23 
GG 7 22% 8 27%    (AA vs AG+GG) 
ACS             MEI vs MEU     
  
genotype MEI (n) MEI (%) MEU (n) MEU (%) 
Dominance 
deviation 
OR 95% CI  p value  
L-SIGN 
rs2277998 
AA 1 4,50% 2 5% 
 
 0.44 to 2.56 0.896 AG 10 45,50% 17 43% 0.85 1.06  
GG 11 50,00% 21 53%   (per A allele) 
DC-SIGN -
139 
AA 5 22,70% 10 25% 
 
 0.36 to 1.38 0.3 AG 5 22,70% 16 40% 0.22 0.70  
GG 12 54,50% 14 35%  (per A allele) 
DC-SIGN -
336 
AA 15 68,20% 28 70% 
 
 0.55 to 2.60 0.65 AG 4 18,20% 9 23% 0.50 1.20  
GG 3 13,60% 3 8%  (per G allele) 
DC-SIGN -
871 
AA 13 59,10% 18 45% 
 
 0.36 to 1.74 0.56 AG 6 27,30% 18 45% 0.21 0.79  
GG 3 13,60% 4 10%  (per G allele) 
DC-SIGN -
939 
AA 4 18,20% 7 18% 
 
 0.42 to 1.79 0.71 AG 8 36,40% 18 45% 0.56 0.87 
GG 10 45,50% 15 38%    (per A allele) 
a 
P-value of dominance deviation test        
b 
Dominance deviation p-value < 0.1        
c
 Statistically significant (<0.05)       
 323 
 324 
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 325 
Supplementary Table 1 326 
 
MOSAIC ACS 
Characteristics MEI MEU MEI MEU 
n (total=124) 32 30 22 40 
Mean age ± SD 43.0 ±6.9 48.5 ±7.9 52.0 ±6.9 52.8 ±7.2 
% Male gender 100% 100% 50% 72.5% 
% Dutch Nationality 87.5% 96.7% 86.4% 92.5%  
% HIV positive at entry 100% 100% 0% 0% 
HIV seroconversion during follow-up n.a n.a 13.6% 0%  
Median start date of Follow-up (IQR) 
22/2/2011 
(4/2/2010-
2/8/2011) 
14/2/2011 
(19/5/2010-
20/12/2011) 
23/2/1988 
(15/1/1987-
08/02/1992) 
20/10/1992 
(12/09/1988-
22/04/1998) 
Median time of follow-up ± SD 4.01 ± 1.80 3.78 ± 1.30 14.96 ± 5.65 14.31 ±5.62 
Mean duration IDU in years 
4 IDU in last 6 
months (no 
duration) 
n.a 7.21 ±3.42 8.45±4.83 
% Reported sharing of needles
§
 0% 0% 75% 55% 
Having an HCV-infected sex partner* 7 1 n.a n.a 
Fisting
§
 
    
With steady partner 9 5 n/a n/a 
With casual partner(s) 10 8 n/a n/a 
Use of sex toys
§
 
    
With steady partner 13 12 n/a n/a 
With casual partner(s) 15 4 n/a n/a 
Rectal bleeding during or after sex
§
 
    
With steady partner ` 10 n/a n/a 
With casual partner(s) 15 8 n/a n/a 
Groupsex
§
 24 23 n/a n/a 
Rectal bleeding during or after sex* 17 5   
CD4 count last negative 
moment(cases)/last visit (controls)* 
523±138 621±222 n.a n.a 
CD4 count nadir 277±160 269±179 n.a n.a 
Baseline Mosaic Risk score (medium)*
#
  2,9  1,1     
 327 
n.a. = not applicable,  328 
* = p < 0,05   329 
§ 
reported at least once 330 
#
 [10] 331 
 332 
 333 
 334 
 335 
 336 
 337 
 338 
 339 
 340 
 341 
 342 
 343 
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Supplementary table 21 344 
Name Orientation Primer sequence 5'-> 3' fragment length 
L-SIGN repeat 
Fwd CCTAAGTCAGGAACAATCCGA 
284bp, 353bp, 422bp, 
491bp, 560bp, 629bp, 
698bp 
(3/4/5/6/7/8/9 
repeats, respectively) 
Rev GAACTCACCAAATGCAGTCTTCAAATC 
L-SIGN SNP rs2277998 
Fwd GTCTAACTCCCAGCGGA 
45bp 
Rev TGGCAGGCGGTGACG 
DC-SIGN promotor PCR 1 
Fwd GCAGTCTTGGTTCCTTGGAG 
630bp 
Rev ACTTGCAGTGCCTCCTCAGT 
DC-SIGN promotor PCR 2 
Fwd TGCTGCTGTCCTCATTTTTG 
638bp 
Rev AGCATACAGAAACCCCGTTG 
Mutagenesis primer -139 
Fwd TAGGGATCTGTCATCCAAAAGGCTAGTGGAAAGCATCAGAGCA 
 Rev TGCTCTGATGCTTTCCACTAGCCTTTTGGATGACAGATCCCTA 
 
Mutagenesis primer -871 
Fwd AGTACTAGTACATTTAATAACGTAGATAAATCTCACAAAACAG 
 Rev CTGTTTTGTGAGATTTATCTACGTTATTAAATGTACTAGTACT 
 
Mutagenesis primer -939 
Fwd CACACTGTAAGATTTGATTTTATGTGAATTTTGAGAACAGGCA 
Rev TGCCTGTTCTCAAAATTCACATAAAATCAAATCTTACAGTGTG 
 
                                                          
1 Amplification conditions:  
L-SIGN repeat: denaturation at 95°C for 5 min, followed by 45 cycles at 95°C for 30s, 60°C for 30s and 72°C for 1 min and a final 
extension step at 72°C for 10 min. 
L-SIGN SNP rs2277998: 50°C for 2 min, denaturation at 95°C for 10 min, followed by 45 cycles at 95°C for 15s and 60°C for 15s, 72°C 
for 20s, followed by an HRM protocol of 95°C for 1 min, 40°C for 1 min and a fluorescence acquisition step at 60°C for 45s.  
DC-SIGN SNPs: denaturation at 95°C for 5 min, followed by 5 cycles at 94°C for 30s, 61°C for 30s (-0.5°C every cycle) and 72°C for 
45s followed by 32 cycles at 94°C for 30s, 60°C for 30s and 72°C for 45s and a final extension step at 72°C for 10min. 
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Supplementary Table 3 345 
 346 
MOSAIC           MEI vs MEU     
  
genotype MEI (n) MEI (%) MEU (n) 
MEU 
(%) 
OR 95% CI 
 p 
value  
DC-SIGN 
-139 
AA 3 11% 2 25% 
 
0.105 - 1.30   0.09 AG 16 59% 1 13% 0.25  
GG 8 30% 5 63% 
(GG vs 
AG+AA) 
DC-SIGN 
-871 
AA 15 56% 4 50% 
 
0.01 - 0.59 < 0.01 AG 10 37% 0 0% 0.08 
GG 2 7% 4 50% 
(GG vs 
AG+AA) 
DC-SIGN 
-939 
AA 5 19% 5 63% 
 
0.02 - 0.77 0.02 AG 16 59% 0 0% 0.14 
GG 6 22% 3 50% 
 (AA vs 
AG+GG) 
 347 
 348 
 349 
 350 
Supplementary Table 4 351 
 genotype n(%) 
 4/5 4/6 4/7 5 5/6 5/7 5/9 6 6/7 6/9 7 7/9 
MEI 0 (0.0) 0 (0.0) 5 (9.6) 2 (3.8) 2 (3.8) 9 (17.3) 1 (1.9) 1 (1.9) 5 (9.6) 1 (1.9) 22 (42.3) 4 (7.7) 
MEU 1 (1.5) 1 (1.5) 1 (1.5) 6 (8.8) 5 (7.4) 13 (19.1) 1 (1.5) 3 (4.4) 13 (19.1) 0 (0.0) 24 (35.3) 0 (0.0) 
 352 
 353 
 354 
Supplementary Table 5 355 
 
homozygous heterozygous OR p value 
MEI 25 (48.1%) 27 (51.9%) 0.9820 0.9608 
MEU 33 (48.5%) 35 (51.5%) 
  Total 58 (48.3%) 62 (51.7%)   
  356 
` 357 
 358 
 359 
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Fig 1 362 
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Fig S1 366 
